Prominent publications by Angela A Dispenzieri

KOL Index score: 21794

BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma ...

Known for Newly Diagnosed Myeloma |  3 Trial |  Dexamethasone Patients |  Swog S0777 |  Bortezomib Lenalidomide
KOL Index score: 18925

Importance: Transthyretin cardiac amyloidosis (also known as ATTR cardiac amyloidosis) is an increasingly recognized cause of heart failure with preserved ejection fraction. In single-center studies, technetium 99m pyrophosphate (Tc 99m PYP) cardiac imaging noninvasively detects ATTR cardiac amyloidosis, but the accuracy of this technique in a multicenter study and the association of Tc 99m PYP myocardial uptake with survival are unknown.

Objective: To assess Tc 99m PYP cardiac imaging ...

Known for Attr Cardiac Amyloidosis |  Cardiac Imaging |  Technetium 99 |  Multicenter Study |  Preserved Ejection Fraction
KOL Index score: 15267

DISEASE OVERVIEW: POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnoses are often delayed ...

Known for Poems Syndrome |  Patients Plasma Cell |  Major Criteria |  Risk Stratification |  Systemic Therapy
KOL Index score: 14881

Autologous stem cell transplantation (ASCT) improves survival in patients with previously untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non-Hodgkin lymphoma (NHL). Lower relapse rates seen in allogeneic stem cell transplantation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-verus-tumor effect. In ASCT, the relation between ALC recovery and clinical outcomes in MM and NHL was not previously ...

Known for Patients Alc |  Superior Survival |  500 Cells Microl |  Lymphocyte Recovery |  Hematopoietic Stem
KOL Index score: 13958

Autologous hematopoietic stem cell transplantation (AHCT) improves survival in patients with multiple myeloma (MM) but is associated with morbidity and nonrelapse mortality (NRM). Hematopoietic cell transplant comorbidity index (HCT-CI) was shown to predict risk of NRM and survival after allogeneic transplantation. We tested the utility of HCT-CI as a predictor of NRM and survival in patients with MM undergoing AHCT. We analyzed outcomes of 1156 patients of AHCT after high-dose melphalan ...

Known for Cell Transplantation |  Multiple Myeloma |  Hctci Score |  Autologous Hematopoietic |  Patients Mm
KOL Index score: 13538

BACKGROUND: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The APOLLO study assessed the efficacy and tolerability of patisiran in patients with hATTR amyloidosis. The effects of patisiran on cardiac structure and function in a prespecified subpopulation of patients with evidence of cardiac amyloid involvement at baseline were assessed.

METHODS: APOLLO was an international, ...

Known for Cardiac Parameters |  Patisiran Patients |  Rna Interference Therapeutic |  Amyloid Neuropathies |  18 Months
KOL Index score: 12816

Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting ...

Known for Plasma Exchange |  Cast Nephropathy |  Free Light Chains |  Renal Disease |  Multiple Myeloma Treatment
KOL Index score: 12807

Myeloma kidney is the major cause of severe irreversible renal failure in patients with multiple myeloma. This tubulointerstitial injury is a direct consequence of high concentrations of circulating monoclonal free light chains (FLCs) produced by a clonal expansion of plasma cells. Early reduction of serum FLCs associates with renal recovery, but the target threshold of reduction to facilitate renal recovery is unknown. To determine the relationship between the achieved FLC reduction and ...

Known for Renal Recovery |  Myeloma Kidney |  Light Chains |  Flc Reduction |  Aged 80
KOL Index score: 12662

BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is defined by expression of heavy-chain immunoglobulin (IgH) and is the precursor lesion for 80% of cases of multiple myeloma. The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS.

METHODS: We used a population-based cohort, previously assembled to estimate MGUS prevalence, of 21,463 residents of Olmsted County, MN, USA, ...

Known for Undetermined Significance |  Light Chain |  Risk Progression |  Mgus Prevalence |  Monoclonal Gammopathy
KOL Index score: 12446

A specific role for increased level of expression of CKS1B, as a consequence of chromosome 1q21 copy number gain, has been postulated as both pathogenic, as well as a powerful clinical prognostic factor in multiple myeloma (MM). The purpose of this study is to determine the clinical associations and prognostic impact of copy number gain at chromosome 1q21 (with a bacteria artificial chromosome clone containing CKS1B) and CKS1B gene level of expression in MM. We studied the chromosome ...

Known for Situ Hybridization |  1q21 Gain |  Cks1b Expression |  Multiple Myeloma Mm |  Myeloma Patients
KOL Index score: 12259

OBJECTIVE: POEMS syndrome (the acronym reflects the common features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein and Skin changes) is a paraneoplastic disorder with a 'demyelinating' peripheral neuropathy that is often mistaken for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The nerve conduction study (NCS) and electromyography (EMG) attributes that might differentiate POEMS from CIDP and lead to earlier therapeutic intervention were ...

Known for Poems Syndrome |  Axonal Loss |  Chronic Inflammatory Cidp |  Nerve Conduction |  Monoclonal Protein
KOL Index score: 12207

PURPOSE: There is consensus that patients with light chain (AL) amyloidosis with hypercalcemia, renal failure, anemia, and lytic bone lesions attributable to clonal expansion of plasma cells (CRAB criteria) also have multiple myeloma (MM). The aim of this study was to examine the spectrum of immunoglobulin AL amyloidosis with and without MM, with a goal of defining the optimal bone marrow plasma cell (BMPC) number to qualify as AL amyloidosis with MM.

PATIENTS AND METHODS: We identified ...

Known for Multiple Myeloma |  Patients Amyloidosis |  Plasma Cells |  Bone Marrow |  Immunoglobulin Light
KOL Index score: 12172

BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear.

METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering ...

Known for Multiple Myeloma |  Risk Progression |  Bone Marrow |  5 Years |  Criteria Diagnosis
KOL Index score: 12020

BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches.

METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 ...

Known for Lenalidomide Dexamethasone |  18 Cycles |  Ineligible Patients |  Interim Analysis |  72 Weeks


Angela A Dispenzieri: Influence Statistics

Sample of concepts for which Angela A Dispenzieri is among the top experts in the world.
Concept World rank
2—diagnostic criteria utilization #1
kidney light #1
candidates systemic therapy #1
uninvolved flc #1
fgn glomeruli #1
flcdiff #1
oligomers patients #1
patients poems syndrome #1
attrwt patients htx #1
maintenance bortezomib induction #1
nxg #1
flc diff #1
poems syndrome asct #1
pjbd #1
cell disorder #1
diagnosis poems #1
poems syndrome apbsct #1
mass‐fix #1
epineurial neovascularization cidp #1
minor features #1
srm mprotein #1
amyloidosis ineligible #1
hhv8mcd #1
poems #1
ife flc #1
nonbiopsy diagnosis #1
igh translocations #1
polyneuropathy improvement #1
allcause mortality amyloidosis #1
presenting complication #1
mflcs ife #1
diagnosis poems syndrome #1
fat aspirate #1
monoclonalproteins #1
uex patients #1
patients maintenance bortezomib #1
flcs plasma #1
reusing daratumumab #1
poems syndrome diagnosis #1
impact scr #1
mgfd fgn #1
patients b2m #1
tourmalineal1 #1
tissue shipping #1
nanobody enrichment #1
major criteria #1
pcd minor criteria #1
microflowlcesiqtof #1
clonotypic peptides srm #1
monoclonal humans mass #1

Key People For Multiple Myeloma

Top KOLs in the world
Kenneth Carl Anderson
multiple myeloma mm cells board directors
Robert A Kyle
multiple myeloma undetermined significance consultancy funding
Sundararajan Vincent Rajkumar
multiple myeloma consultancy funding undetermined significance
Paul Gerard Guy Richardson
multiple myeloma board directors advisory committees
JesusFernando San San Miguel
multiple myeloma consultancy honoraria board directors
Bart Barlogie
multiple myeloma total therapy gene expression

Angela A Dispenzieri:Expert Impact

Concepts for whichAngela A Dispenzierihas direct influence:Multiple myeloma,  Poems syndrome,  Stem cell,  Light chain,  Cell transplantation,  Monoclonal gammopathy,  Undetermined significance,  Cardiac amyloidosis.

Angela A Dispenzieri:KOL impact

Concepts related to the work of other authors for whichfor which Angela A Dispenzieri has influence:Multiple myeloma,  Cardiac amyloidosis,  Poems syndrome,  Stem cell,  Monoclonal gammopathy,  Bone marrow,  Undetermined significance.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA | Division of Hematology, Mayo Clinic, Rochester, MN, USA. | Division of Hematology, Mayo Clinic Rochester, MN, USA | Mayo Clinic, Rochester, MN | Mayo Cl

FREE Custom List